Annual ROE
-173.34%
-87.51%-101.96%
31 December 2023
Summary:
Inhibikase Therapeutics annual return on equity is currently -173.34%, with the most recent change of -87.51% (-101.96%) on 31 December 2023. During the last 3 years, it has fallen by -65.76% (-61.13%). IKT annual ROE is now -162.65% below its all-time high of 276.67%, reached on 31 December 2018.IKT ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
-350.62%
-156.45%-80.57%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly return on equity is currently -350.62%, with the most recent change of -156.45% (-80.57%) on 30 September 2024. Over the past year, it has dropped by -255.96% (-270.40%). IKT quarterly ROE is now -249.99% below its all-time high of 233.76%, reached on 31 December 2020.IKT Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -102.0% | -270.4% |
| 3 y3 years | -61.1% | -558.9% |
| 5 y5 years | -162.7% | - |
IKT ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -350.4% | at low | -749.2% | at low |
| 5 y | 5 years | -162.7% | at low | -250.0% | +55.1% |
| alltime | all time | -162.7% | at low | -250.0% | +55.1% |
Inhibikase Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -350.62%(+80.6%) |
| June 2024 | - | -194.17%(+32.1%) |
| Mar 2024 | - | -147.03%(+36.7%) |
| Dec 2023 | -173.34%(+102.0%) | -107.54%(+13.6%) |
| Sept 2023 | - | -94.66%(+13.1%) |
| June 2023 | - | -83.69%(+18.1%) |
| Mar 2023 | - | -70.86%(+7.6%) |
| Dec 2022 | -85.83% | -65.84%(+11.1%) |
| Sept 2022 | - | -59.24%(+14.3%) |
| June 2022 | - | -51.81%(+25.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | -41.29%(-4.6%) |
| Dec 2021 | -38.49%(-64.2%) | -43.28%(-18.7%) |
| Sept 2021 | - | -53.21%(-18.3%) |
| June 2021 | - | -65.11%(-91.7%) |
| Mar 2021 | - | -780.41%(-433.9%) |
| Dec 2020 | -107.58%(-184.4%) | 233.76%(+440.6%) |
| Sept 2020 | - | 43.24%(-22.6%) |
| June 2020 | - | 55.88%(-43.4%) |
| Mar 2020 | - | 98.65%(-22.6%) |
| Dec 2019 | 127.46%(-53.9%) | 127.46% |
| Dec 2018 | 276.67% | - |
FAQ
- What is Inhibikase Therapeutics annual return on equity?
- What is the all time high annual ROE for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual ROE year-on-year change?
- What is Inhibikase Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly ROE year-on-year change?
What is Inhibikase Therapeutics annual return on equity?
The current annual ROE of IKT is -173.34%
What is the all time high annual ROE for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual return on equity is 276.67%
What is Inhibikase Therapeutics annual ROE year-on-year change?
Over the past year, IKT annual return on equity has changed by -87.51% (-101.96%)
What is Inhibikase Therapeutics quarterly return on equity?
The current quarterly ROE of IKT is -350.62%
What is the all time high quarterly ROE for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly return on equity is 233.76%
What is Inhibikase Therapeutics quarterly ROE year-on-year change?
Over the past year, IKT quarterly return on equity has changed by -255.96% (-270.40%)